

Clinical Potential of Effective Noninvasive Exclusion of *KEL1*-Positive Fetuses in *KEL1*-Negative Pregnant Women

Jana Böhmova^a Radek Vodicka^a Marek Lubusky^a Iva Holuskova^a
Martina Studnickova^a Romana Kratochvilova^a Eva Krejcirikova^a
Maria Janikova^a Veronika Durdová^a Tereza Dolezalová^a Hana Filipová^a
Ladislav Dusek^b Ishraq Dhaifalah^a Katherine Vomackova^a
Marian Kacerovsky^c Martin Prochazka^a Radek Vrtel^a

^aUniversity Hospital and Palacky University Olomouc, Olomouc, ^bMasaryk University Institute of Biostatistics and Analyses, Brno, and ^cUniversity Hospital Hradec Kralove, Hradec Kralove, Czech Republic

Key Words

Noninvasive fetal genotyping · *KEL1* · Minisequencing · Kell blood group system · Red blood cell alloimmunization · Hemolytic disease of the fetus and newborn

Abstract

Background: The clinical importance of assessing the fetal *KEL* genotype is to exclude 'K'-positive fetuses (genotype *KEL1/KEL2*) in 'K'-alloimmunized pregnant women (genotype *KEL2/KEL2*). Noninvasive assessment of the fetal *KEL* genotype is not yet available in the Czech Republic. **Objective:** The aim of this study was to assess the fetal *KEL1/KEL2* genotype from cell-free fetal DNA in the plasma of *KEL2/KEL2* pregnant women. **Methods:** The fetal genotype was assessed by minisequencing (a dilution series including control samples). A total of 138 pregnant women (between the 8th and 23rd gestational week) were tested by minisequencing. The fetal genotype was further verified by analysis of a buccal swab from the newborn. **Results:** Minisequencing proved to be a reliable method. In 2.2% (3/138) of the exam-

ined women, plasma sample testing failed; 94.8% (128/135) had the *KEL2/KEL2* genotype, and a total of 3.1% of fetuses (4/128) had the *KEL1/KEL2* genotype. Sensitivity and specificity reached 100% ($p < 0.0001$). **Conclusion:** Minisequencing is a reliable method for the assessment of the fetal *KEL1* allele from the plasma of *KEL2/KEL2* pregnant women.

© 2015 S. Karger AG, Basel

Introduction

In pregnant women diagnosed with red blood cell alloantibody anti-K ('K'-negative, genotype *KEL2/KEL2*), the fetuses are at risk of hemolytic disease only if antigen 'K' ('K'-positive, genotype *KEL1/KEL2*) is present on their erythrocytes. In reality, however, approximately 95% of fetuses are 'K'-negative (genotype *KEL2/KEL2*) and thus are not at risk of hemolytic disease [1]. The clinical importance of assessing the fetal *KEL* genotype is to exclude 'K'-negative fetuses (genotype *KEL2/KEL2*) in 'K'-negative pregnant women. Maternal anti-K antibod-

ies that penetrate through the placenta during incompatible pregnancy cause suppression of erythropoiesis. The 'K' antigen is expressed by erythroid precursor cells, in contrast to the Rh proteins that are expressed on the surface of mature erythrocytes. In this case, the level of maternal anti-K antibodies is not a good indicator of hemolytic disease of the fetus and newborn [2, 3]. Noninvasive assessment of the fetal *KEL* genotype is not yet available in the Czech Republic.

The *KEL* gene has two major co-dominant alleles: *KEL1* and *KEL2*. The difference in the gene sequence between the *KEL1* and *KEL2* alleles is caused by a single nucleotide substitution in exon 6 at position 578 (c.578C>T, rs8176058); the presence of T characterizes the *KEL1* allele and the presence of C characterizes the *KEL2* allele [4, 5]. The single nucleotide change 578C>T results in the substitution of threonine ('k') to methionine ('K') at position 193 (p.Thr193Met) [6, 7]. For the detection of particular alleles, allele-specific polymerase chain reaction (AS-PCR) or PCR with subsequent cleavage by restriction enzyme *BsmI* (PCR-RFLP) may be used [5, 8–11]. It is also possible to use more sensitive and faster detection methods, such as allelic discrimination using TaqMan PCR, minisequencing using the SNaPshot system (Applied Biosystems, USA) or a DNA microarray platform [7, 10]. Briefly, minisequencing is composed of PCR amplification for the formation of PCR products containing the target SNP and a single base extension (SBE) of the oligonucleotide primer using a fluorescently labeled dideoxynucleotide base at the 3' end of each primer located proximal to the target SNP (minisequencing PCR). The length and type of fluorescence dye of the single base extended primer (for a particular SNP) is detected by capillary electrophoresis. For noninvasive prenatal *KEL1/KEL2* genotyping, SABER-based MALDI-TOF mass spectrometry and TaqMan PCR are used [12–14].

The aim of this work was to utilize the minisequencing method for noninvasive *KEL1/KEL2* (c.578C>T) genotyping to design and test a reliable diagnostic strategy that is applicable to routine practice.

Methods

Peripheral blood samples of pregnant women, confirmation samples of newborn buccal swabs and control plasma samples for calibration and optimization were collected in collaboration with the Department of Medical Genetics, the Department of Obstetrics and Gynecology and the Department of Transfusion Medicine of the University Hospital Olomouc. All of the women enrolled in the study signed an informed consent form approved by the Ethics

Table 1. Summary of the analyzed samples

Type of primary sample	Plasma samples (cff DNA)	Newborn DNA
Total number of analyzed samples	138	128
Non-analyzable samples	3	–
<i>KEL1/KEL2</i> heterozygous pregnant women	7	–
Negative <i>KEL2/KEL2</i> pregnant women	128	128
<i>KEL1/KEL2</i> samples	26	4
<i>KEL2/KEL2</i> samples	102	124
False-positive <i>KEL1/KEL2</i> samples	22	0
False-negative <i>KEL2/KEL2</i> samples	0	0

Committee of the University Hospital Olomouc. The number of samples analyzed using minisequencing was as follows: the analysis was performed in 138 randomly selected plasma samples taken from pregnant women >18 years with a singleton pregnancy between 8 and 23 gestational weeks and 128 control newborn buccal swabs (table 1). The mean and median gestational age was 13 and 12 weeks, respectively.

All of the blood samples (samples and control) were collected into two parallel 9-ml tubes ('A' and 'B') containing ethylenediaminetetraacetic acid. Anticoagulated blood was placed on ice immediately after collection and was processed up to 4 h after sampling. Plasma was separated from the cellular fraction of blood using double centrifugation (2,700 g for 10 min and 3,500 g for 20 min). The plasma samples were frozen until further processing at –28°C. Plasma cell-free (cf) DNA was isolated in each of two parallel tubes ('A' and 'B'). The DNA isolation of 1 ml of plasma was performed using the QIAamp DNA Mini Kit (Qiagen, USA). The incubation step for the isolation took place at 56°C, with an elution volume of 65 µl. Plasma cf DNA for the dilution series was obtained using a QIAamp DNA Mini Kit from 5 ml of plasma eluted in a 325-µl total volume under the conditions described above. The isolation of the control DNA from newborn buccal swabs was performed using a QIAamp DNA Mini kit according to the manufacturer's instructions.

The dilution series was prepared to determine the sensitivity threshold of capillary electrophoresis minisequencing and to simulate the *KEL1* heterozygous admixture genotype of the fetus in a *KEL2/KEL2* mother. The dilution series were created using an artificial DNA mixture of diluted genotypes of serologically proven *KEL1/KEL2* heterozygous and *KEL2/KEL2* homozygous samples from an initial concentration of 5 ng/µl (measured using the Quantifiler Human DNA Quantification Kit, Applied Biosystems, USA). The calibration range for minisequencing was 0.78–100%.

The SNaPshot system was used for minisequencing *KEL1/KEL2* detection and quantification. The first PCR amplification was performed with the primers used by Poole et al. [7] as originally determined for real-time PCR. The PCR primer sequences were GGA GGC TGG CGC ATC TC, forward, and GCA GGA TGA GGT CCT A, reverse. The samples were analyzed in two parallel reactions ('A' and 'B'). The PCR plasma cell-free fetal (cff) DNA and plasma cf DNA samples in the dilution series were amplified in a final 25-µl volume. The PCR premix contained 12.5 µl of Combi PPP Master Mix (Top-Bio, USA), 0.5 µl of forward primer (10 pmol/l) (Sigma-Aldrich, USA), 0.5 µl of reverse prim-




Fig. 1. The calibration curve of 0.78–100% artificial plasma cf DNA mixtures of heterozygous *KEL1/KEL2* in a *KEL2/KEL2* homozygote sample. The x axis shows the RFU ratio of *KEL1/KEL2* in *KEL2/KEL2* measured by peak height. The y axis shows the percentage of the *KEL1/KEL2* DNA concentration in *KEL2/KEL2* samples.

er (10 pmol/l) (Sigma-Aldrich, USA) and 11.5 μ l of plasma cf DNA samples or plasma cf DNA samples from the dilution series. PCR amplification with DNA samples isolated from control buccal swabs of newborns was performed in a final volume of 12.5 μ l. The PCR premix for the buccal swab DNA contained 6.25 μ l of Combi PPP Master Mix, 5.25 μ l of PCR water (Top-Bio, USA), 0.25 μ l of forward primer (10 pmol/l) (Sigma-Aldrich, USA), 0.25 μ l of reverse primer (10 pmol/l) (Sigma-Aldrich, USA) and 1 μ l of DNA. PCR for all samples was performed in a Thermocycler C1000 (Bio-Rad, USA) under the following conditions: 95°C for 10 min (95°C for 30 s, 59.5°C for 1 min, 72°C for 1 min) 35 times, and 72°C for 10 min. Following purification of the PCR products, enzymatic purification using exonuclease (Exonuclease I; Thermo Scientific, USA) and alkaline phosphatase (FastAP Thermosensitive Alkaline Phosphatase; Thermo Scientific, USA) was performed according to the manufacturer's instructions. A minisequencing extension reaction was performed using the SBE primer: 24T-TGG TAA ATG GAC TTC CTT AAA CTT TAA CCG AA [10]. Amplification was performed using the ABI PRISM SNaPshot Multiplex Kit (Applied Biosystems, USA) in a final volume of 8 μ l. The plasma sample amplification mix contained 4 μ l of SNaPshot Multiplex Ready Reaction Mix, 1 μ l of SBE primer (10 pmol/l) (Sigma-Aldrich, USA) and 3.5 μ l of purified PCR product from plasma cf DNA samples or plasma cf DNA samples from the dilution series. The SNaPshot premix for buccal swab DNA contained 4 μ l of SNaPshot Multiplex Ready Reaction Mix, 0.5 μ l of SBE primer (10 pmol/l) (Sigma-Aldrich, USA), 1.5 μ l of PCR water (Top-Bio, USA) and 2 μ l of purified PCR product from buccal swabs. Purification of the products used for minisequencing was performed with an alkaline phosphatase enzyme (FastAP Thermosensitive Alkaline Phosphatase) according to the ABI PRISM SNaPshot

Multiplex Kit protocol. Fluorescence intensity and size of the minisequencing products were determined by capillary electrophoresis on a Genetic Analyzer ABI PRISM 3130 (Applied Biosystems, USA) using polymer NanoPOP-7 (MCLAB, USA) and a capillary 36 cm in length. One microliter of purified minisequencing product was mixed with 8.5 μ l of Hi-Di formamide (Applied Biosystems, USA) and 0.5 μ l of GeneScan-120 LIZ Size Standard (Applied Biosystems, USA). Each sample of plasma cf DNA was assessed in two capillary electrophoresis conditions. The first injection was for 5 s at 1.2 kV with electrophoresis for 27 min at 15 kV, and the second injection was for 16 s at 1.2 kV with electrophoresis for 27 min at 15 kV. The capillary conditions for the buccal swab samples were injection for 5 s at 1.2 kV with electrophoresis for 27 min at 15 kV. The data were analyzed by GeneMapper v 4.1. Quantification was assessed using the *KEL1* peak relative fluorescence unit (RFU) and the *KEL1/KEL2* peak RFU ratio.

For statistical analysis, calibration curves were computed using a nonlinear regression polynomial model of the third order with the best fit. The discrimination ability of signals for *KEL1* was analyzed using receiver operating characteristic (ROC) curves and described by the area under curve with corresponding 95% confidence intervals and statistical significance. Cut-off values were derived according to the sum of the sensitivity and specificity values. Statistical analysis was performed using SPSS 22 (IBM Corporation, 2013).

Results

The minisequencing calibration analyses showed only C/T nucleotide-specific peaks that were visible at concentrations of at least 0.78% (equivalent to 0.039 ng/ μ l) of *KEL1/KEL2* in the *KEL2/KEL2* admixture. The ratio of the RFU (*KEL1/KEL2*) values was 0.041 in 0.78% of the admixture (fig. 1).

The analysis repeatedly failed in 3/138 plasma samples. The signal intensity of PCR products (both maternal and fetal) was undetectable. The failure was probably caused by very low concentration of DNA in plasma due to DNA degradation during sample handling (transport, plasma acquisition, DNA isolation, etc.). Seven of 135 analyzable plasma samples could not be genotyped due to maternal heterozygosity. The heterozygosity *KEL1/KEL2* is very clearly visible and detectable from maternal plasma as the maternal fluorescent signal from *KEL1* and *KEL2* alleles is quantitatively comparable (see online supplement 1; for all online suppl. material, see www.karger.com/doi/10.1159/000441296). The genotype frequencies were 94.8% for *KEL2/KEL2* and 5.2% for *KEL1/KEL2*. The *KEL1* RFU measurements were performed in 128 plasma *KEL2/KEL2* samples, of which four were truly *KEL1*-positive (fig. 2, online supplement 2). Plasma cf DNA concentration was evaluated from the calibration curve (fig. 1) with the assumption that PCR efficiency and

RFU ratio of artificial mixtures in plasma cf DNA are similar to the admixture of plasma cf DNA in maternal plasma cf DNA.

The results were confirmed with newborn DNA (table 1). About one order weaker false-positive *KEL1* RFU signals were observed in 22 samples in one or two of four measurements, corresponding to approximately 0.01–0.02% of *KEL1* signals (table 1). This very low signal (RFU about 20) could be caused by the very sensitive fluorescent baseline. The four true *KEL1* signals (RFU from 200 to 500) were detected in all four measurements for each sample (0.4–0.9%) and postnatally confirmed (*KEL1/KEL2* samples). Gestational week of the lower signal-positive sample (0.4%) was 10, the remaining three samples (about 0.9%) were gestational weeks 12, 12 and 13. Using aggregated measurements the tested sensitivity and specificity reached 100% (table 2, fig. 3). No false *KEL2/KEL2* sample was detected.

Discussion

The frequency of the *KEL1* allele is population-specific and ranges from 2.2 to 4.6% in European populations [15–17]. The *KEL1* allelic frequency in our sample collection of pregnant women was close to the lower border of this range (2.6%) and corresponds with data from National Center for Biotechnology Information [17]. The *KEL1/KEL2* heterozygous father genotype demonstrates a theoretical 50% probability that the fetus of a *KEL2/KEL2* woman inherits the paternal *KEL1* allele. We found a 3.1% *KEL1/KEL2* prevalence of heterozygous fetuses in *KEL2/KEL2* homozygous pregnant women, which correlates with 2.6% of the theoretical probability of incidence of the fetal *KEL1* allele in the general population.

We also tested the TaqMan real-time PCR method for the noninvasive determination of *KEL1* that is suitable for SNP discrimination. We determined that real-time PCR using TaqMan probes was unsuitable for distinguishing *KEL1*-positive and *KEL1*-negative pregnancies, probably due to the nonspecific binding of the *KEL1* probe to the *KEL2* allele [18]. More specific SNP detection can be achieved using locked nucleic acid probe-based real-time PCR. Locked nucleic acid-based *KEL1* genotyping showed increased specificity of the complementary DNA strand. It is thermally stable and has excellent mismatch discrimination. Finning et al. [12] used this variant of real-time PCR for noninvasive *KEL1* genotyping. The method increased the detection specificity of the *KEL1* allele, although its sensitivity was reduced.




Fig. 2. The projection of *KEL1*-positive plasma samples onto the calibration curve. The x axis shows the RFU ratio of *KEL1/KEL2* in *KEL2/KEL2* measured by peak height. The y axis shows the percentage of the *KEL1/KEL2* DNA concentration in *KEL2/KEL2* samples. The black circles represent four true *KEL1/KEL2* plasma samples.




Fig. 3. The discrimination power of the RFU ratio (*KEL1/KEL2*) for *KEL1* positivity using aggregated measurements. The ROC curve was used for discrimination power assessment to distinguish true *KEL1/KEL2* from false *KEL1/KEL2* samples. This curve shows the ROC analysis based on the average RFU *KEL1/KEL2* ratios of all four measurements in each of the 128 samples.

Table 2. Discrimination power of the *KEL1* signal for positivity by a RFU measurement of the *KEL1* signal and on the basis of the *KEL1/KEL2* RFU ratio (sample size n = 128)

Capillary condition ¹	Sample A 1st injection	Sample B 1st injection	Sample A 2nd injection	Sample B 2nd injection	Aggregated measurements ² 1st and 2nd injection
Cut-off (RFU of <i>KEL1</i> signal)	≥12.5	≥19	≥126	≥122.5	–
Cut-off (<i>KEL1/KEL2</i> RFU ratio)	≥0.012	≥0.014	≥0.022	≥0.023	≥0.020
Sensitivity (RFU of <i>KEL1</i> signal)	1.000	1.000	1.000	1.000	–
Sensitivity (<i>KEL1/KEL2</i> RFU ratio)	1.000	1.000	1.000	1.000	1.000
Specificity (RFU of <i>KEL1</i> signal)	0.984	1.000	1.000	0.992	–
Specificity (<i>KEL1/KEL2</i> RFU ratio)	0.984	1.000	1.000	0.992	1.000
AUC ³ (RFU of <i>KEL1</i> signal)	0.996	1.000	1.000	0.992	–
AUC ³ (<i>KEL1/KEL2</i> RFU ratio)	0.990	1.000	1.000	0.998	1.000
p ⁴ (RFU of <i>KEL1</i> signal)	<0.001	<0.001	<0.001	<0.001	–
p ⁴ (<i>KEL1/KEL2</i> RFU ratio)	<0.001	<0.001	<0.001	<0.001	<0.001

¹ Capillary condition of the 1st injection was 5 s, 1.2 kV and of the 2nd injection 16 s, 1.2 kV, 15 kV. ² Aggregated measurements were performed using the average of all measurements on the basis of *KEL1/KEL2* RFU ratio. ³ AUC (area under the curve) is related to the maximum and gives a measure of the quality of the test. ⁴ The p value was calculated with 95% confidence interval.

PNA-Clamp technology is another modification that increases the specificity of a reaction. Peptide nucleic acid (PNA) probes are bound to a complementary strand of DNA with high affinity, and the resulting PNA-DNA duplexes are more thermally stable. The PNA-DNA duplex is destabilized in the presence of the SNP and occurs in the amplification of the mutant allele [19]. Scheffer et al. [13] proposed clamping the PNA to the *KEL2* allele to prevent nonspecific amplification of the *KEL2* allele. This method increased the detection of fetal *KEL1* and also decreased the test sensitivity.

To assess minisequencing for noninvasive *KEL1/KEL2* genotyping, we first replicated the technique described by Di Cristofaro et al. [10] on samples isolated from the leukocytes of peripheral blood. Based on the confirmation of minisequencing specificity, we adapted the methodology for plasma cff DNA genotyping. The plasma cff DNA molecules are largely degraded into shorter fragments under 200 bp [20, 21]. Therefore, we reduced the length of the PCR products from 350 to 124 bp. The plasma cff DNA yield of the *KEL1* allele appeared to be <1% (fig. 2). The amount of plasma cff DNA could be increased using isolation kits that were designed for plasma cff DNA or for smaller DNA molecules. Nevertheless, the kit that we used to isolate the plasma cff DNA is quite commonly used for noninvasive diagnostic purposes [12, 13].

The final low yield of plasma cff DNA can be due to the preferential amplification of maternal DNA during minisequencing. The RFU quantity of positive samples indicates lower cff DNA concentration of the sample from the 10th gestational week compared to three samples from the 12th

and 13th gestational week. Despite the absence of false-negative results in our study, the inclusion of a fetal control marker might have been considered. However, in the case of the most commonly used marker *RASSF1A*, the restriction site of *Bst*UI is close to the *KEL1/KEL2* polymorphism site; thus, this marker is not suitable as a fetal DNA control.

The false-positive (background) *KEL1* signal was very low; the detectable RFU values and their percentages were an order of magnitude lower than those of the true-positive *KEL1* plasma samples. Based on the results of ROC discrimination analysis, minisequencing is most accurate in the sample duplicate method and under two different electrophoresis conditions (fig. 3). The method is sufficiently sensitive and specific despite the relatively lower gain of plasma cff DNA.

The minisequencing method is mainly designed for the detection of the *KEL1* polymorphism (c.578C>T). There are rare SNPs at codon 193 (c.578C>G, c.577A>T). Our method should be able to detect the SNP variant c.578C>G as a different fluorescent signal (blue channel). The variant was not observed in our set of samples. It is also possible to detect the 577A>T variant using specific SBE primer (one nucleotide shorter) in separate minisequencing PCR. Both SNP variants result in the 'K' antigen, but the alloimmune response in this case was weaker and not as clinically significant [3, 7].

In conclusion, we described an effective, sufficiently specific and sensitive minisequencing method that is potentially suitable for the routine diagnosis of fetuses with *KEL1/KEL2* genotypes in pregnant women with *KEL2/KEL2* genotypes.

Acknowledgment

Funding for this study and its publication was provided by grant agency IGA MZ CR: NT12225.

Disclosure Statement

There is no known conflict of interest in this paper.

References

- 1 Lubusky M: Kell aloimmunizace matky muze vest k rozvoji anemie plodu. *Gynekologie po promoci* 2009;9:27–31.
- 2 Stephen J, Cairns LS, Pickford WJ, Vickers MA, Urbaniak SJ, Barker RN: Identification, immunomodulatory activity, and immunogenicity of the major helper T-cell epitope on the K blood group antigen. *Blood* 2012;119:5563–5574.
- 3 Daniels G: Chapter 7: Kell and Kx blood group systems; in *Human Blood Groups*, ed 3. Oxford, Wiley-Blackwell, 2013.
- 4 Reid ME, Denomme GA: DNA-based methods in the immunohematology reference laboratory. *Transfus Apher Sci* 2011;44:65–72.
- 5 Arnoni CP, Muniz JG, de Paula TA, Person RD, Gazito D, Baleotti W Jr, Barreto JA, Castilho L, Latini FR: An easy and efficient strategy for KEL genotyping in a multiethnic population. *Rev Bras Hematol Hemoter* 2013;35:99–102.
- 6 Lee S, Wu X, Reid M, Zelinski T, Redman C: Molecular basis of the Kell (K1) phenotype. *Blood* 1995;85:912–916.
- 7 Poole J, Warke N, Hustinx H, Taleghani BM, Martin P, Finning K, Crew VK, Green C, Bromilow I, Daniels G: A KEL gene encoding serine at position 193 of the Kell glycoprotein results in expression of KEL1 antigen. *Transfusion* 2006;46:1879–1885.
- 8 Avent ND: Antenatal genotyping of the blood groups of the fetus. *Vox Sang* 1998;74:365–374.
- 9 Faas BH, Maaskant-van Wijk PA, von dem Borne AE, van der Schoot CE, Christiaens GC: The applicability of different PCR-based methods for fetal RHD and K1 genotyping: a prospective study. *Prenat Diagn* 2000;20:453–458.
- 10 Di Cristofaro J, Silvy M, Chiaroni J, Bailly P: Single PCR multiplex SNaPshot reaction for detection of eleven blood group nucleotide polymorphisms: optimization, validation, and one year of routine clinical use. *J Mol Diagn* 2010;12:453–460.
- 11 Flores MA, Visentainer JE, Guelsin GA, Fracasso Ade S, de Melo FC, Hashimoto MN, Sell AM: Rh, Kell, Duffy, Kidd and Diego blood group system polymorphism in Brazilian Japanese descendants. *Transfus Apher Sci* 2014;50:123–128.
- 12 Finning K, Martin P, Summers J, Daniels G: Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. *Transfusion* 2007;47:2126–2133.
- 13 Scheffer PG, van der Schoot CE, Page-Christiaens GC, de Haas M: Noninvasive fetal blood group genotyping of rhesus D, C, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. *BJOG* 2011;118:1340–1348.
- 14 Li Y, Finning K, Daniels G, Hahn S, Zhong X, Holzgreve W: Noninvasive genotyping fetal Kell blood group (KEL1) using cell-free fetal DNA in maternal plasma by MALDI-TOF mass spectrometry. *Prenat Diagn* 2008;28:203–208.
- 15 Wagner FF, Kasulke D, Kerowgan M, Flegel WA: Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in southwestern Germany. *Infusionsther Transfusionsmed* 1995;22:285–290.
- 16 Reid ME, Lomas-Francis C: *The Blood Group Antigen Facts Book*, ed 3 (paperback). New York, Elsevier Academic Press, 2012.
- 17 National Center for Biotechnology Information: dbSNP short genetic variations. Available at http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8176058 (accessed July 2, 2014).
- 18 Böhmova J, Vodicka R, Lubusky M, Vrtel R, Holuskova I, Studnickova M, Kratochvilova R, Krejcirikova E, Janikova M: Noninvasive prenatal KEL genotyping using TaqMan real time PCR and by capillary electrophoresis minisequencing. *Eur J Hum Genet* 2014;22 (suppl 1):63.
- 19 Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY: Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. *Lung Cancer* 2012;75:321–325.
- 20 Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR: Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. *Proc Natl Acad Sci USA* 2008;105:16266–16271.
- 21 Vodicka R, Vrtel R, Dusek L, Prochazka M, Schneiderova E, Vrbicka D: Refined fluorescent STR quantification of cell-free fetal DNA during pregnancy in physiological and Down syndrome fetuses. *Prenat Diagn* 2008;28:425–433.